IFNA2 and uveitis: The major experience with the use of IFN-α therapy involves patients affected with Behçet’s disease with response rates of 83 to 92%, within 2 to 4 weeks.57–59 Recently, several reports have also included patients with other causes of uveitis including, sympathetic ophthalmia, Vogt-Koyanagi-Harada disease, birdshot chorioretinopathy, intermediate uveitis, and idiopathic panuveitis57,61.